Skip to main content
bioRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search
New Results

A novel HER2-targeted antibody-drug conjugate offers the possibility of clinical dosing at trastuzumab-equivalent exposure levels

View ORCID ProfileRobyn M. Barfield, Yun Cheol Kim, Stepan Chuprakov, Fangjiu Zhang, Maxine Bauzon, Ayodele O. Ogunkoya, Dominick Yeo, Colin Hickle, Mark D. Pegram, David Rabuka, View ORCID ProfilePenelope M. Drake
doi: https://doi.org/10.1101/2020.03.13.991448
Robyn M. Barfield
1Catalent Biologics, 5959 Horton Street, Ste. 400, Emeryville, CA 94608, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Robyn M. Barfield
Yun Cheol Kim
1Catalent Biologics, 5959 Horton Street, Ste. 400, Emeryville, CA 94608, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stepan Chuprakov
1Catalent Biologics, 5959 Horton Street, Ste. 400, Emeryville, CA 94608, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Fangjiu Zhang
1Catalent Biologics, 5959 Horton Street, Ste. 400, Emeryville, CA 94608, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Maxine Bauzon
1Catalent Biologics, 5959 Horton Street, Ste. 400, Emeryville, CA 94608, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ayodele O. Ogunkoya
1Catalent Biologics, 5959 Horton Street, Ste. 400, Emeryville, CA 94608, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dominick Yeo
1Catalent Biologics, 5959 Horton Street, Ste. 400, Emeryville, CA 94608, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Colin Hickle
1Catalent Biologics, 5959 Horton Street, Ste. 400, Emeryville, CA 94608, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mark D. Pegram
2Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA 94305, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David Rabuka
1Catalent Biologics, 5959 Horton Street, Ste. 400, Emeryville, CA 94608, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Penelope M. Drake
1Catalent Biologics, 5959 Horton Street, Ste. 400, Emeryville, CA 94608, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Penelope M. Drake
  • For correspondence: penelope.drake@catalent.com
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Preview PDF
Loading

Abstract

Trastuzumab and the related antibody-drug conjugate (ADC), ado-trastuzumab emtansine (T-DM1), both target HER2-overexpressing cells. Together, these drugs have treatment indications in both early-stage and metastatic settings for HER2+ breast cancer. T-DM1 retains the antibody functionalities of trastuzumab and adds the potency of a cytotoxic maytansine payload. Interestingly, in the clinic, T-DM1 cannot always replace the use of trastuzumab plus chemotherapy administered together as single agents. We hypothesize that this failure may be due in part to the limited systemic exposure achieved by T-DM1 relative to trastuzumab because of toxicity-related dosing constraints on the ADC. We have developed a trastuzumab-based ADC site-specifically conjugated to maytansine through a noncleavable linker. This construct, termed CAT-01-106, has a drug-to-antibody ratio (DAR) of 1.8, approximately half the average DAR of T-DM1, which comprises a mixture of antibodies variously conjugated with DARs ranging from 0-8. The high DAR species present in T-DM1 contribute to its toxicity and limit its clinical dose. CAT-01-106 showed superior in vivo efficacy compared to T-DM1 at equal payload dosing and was equally or better tolerated compared to T-DM1 at equal payload dosing up to 120 mg/kg in Sprague-Dawley rats and 60 mg/kg in cynomolgus monkeys. CAT-01-106 also showed improved pharmacokinetics in rats relative to T-DM1, with 40% higher ADC exposure levels. Together, the data suggest that CAT-01-106 may be sufficiently tolerable to enable clinical dosing at trastuzumab-equivalent exposure levels, combining the functions of both the antibody and the payload in one drug and potentially improving patient outcomes.

Footnotes

  • Potential conflict of interest: All authors except M.D.P. are employees of Catalent Biologics, which owns the CAT-01-106 molecule. M.D.P. has relationships with Roche/Genentech, Zymeworks, Astra-Zeneca/Daiichi Sankyo.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted March 15, 2020.
Download PDF

Supplementary Material

Email

Thank you for your interest in spreading the word about bioRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
A novel HER2-targeted antibody-drug conjugate offers the possibility of clinical dosing at trastuzumab-equivalent exposure levels
(Your Name) has forwarded a page to you from bioRxiv
(Your Name) thought you would like to see this page from the bioRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
A novel HER2-targeted antibody-drug conjugate offers the possibility of clinical dosing at trastuzumab-equivalent exposure levels
Robyn M. Barfield, Yun Cheol Kim, Stepan Chuprakov, Fangjiu Zhang, Maxine Bauzon, Ayodele O. Ogunkoya, Dominick Yeo, Colin Hickle, Mark D. Pegram, David Rabuka, Penelope M. Drake
bioRxiv 2020.03.13.991448; doi: https://doi.org/10.1101/2020.03.13.991448
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
A novel HER2-targeted antibody-drug conjugate offers the possibility of clinical dosing at trastuzumab-equivalent exposure levels
Robyn M. Barfield, Yun Cheol Kim, Stepan Chuprakov, Fangjiu Zhang, Maxine Bauzon, Ayodele O. Ogunkoya, Dominick Yeo, Colin Hickle, Mark D. Pegram, David Rabuka, Penelope M. Drake
bioRxiv 2020.03.13.991448; doi: https://doi.org/10.1101/2020.03.13.991448

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Pharmacology and Toxicology
Subject Areas
All Articles
  • Animal Behavior and Cognition (4682)
  • Biochemistry (10357)
  • Bioengineering (7670)
  • Bioinformatics (26332)
  • Biophysics (13523)
  • Cancer Biology (10684)
  • Cell Biology (15438)
  • Clinical Trials (138)
  • Developmental Biology (8497)
  • Ecology (12821)
  • Epidemiology (2067)
  • Evolutionary Biology (16853)
  • Genetics (11399)
  • Genomics (15478)
  • Immunology (10616)
  • Microbiology (25208)
  • Molecular Biology (10220)
  • Neuroscience (54465)
  • Paleontology (401)
  • Pathology (1668)
  • Pharmacology and Toxicology (2897)
  • Physiology (4342)
  • Plant Biology (9245)
  • Scientific Communication and Education (1586)
  • Synthetic Biology (2557)
  • Systems Biology (6780)
  • Zoology (1466)